source
- Par Health initiates voluntary recall of Argatroban injection after detecting particulate contaminantsPar Health USA announced a voluntary nationwide recall of its Argatroban Injection 250 mg/2.5 mL product, affecting 22 lots that have been distributed to hospitals and users. The recall was trigge…
- FDA approves oral decitabine/cedazuridine plus venetoclax for older AML patients unable to tolerate intensive chemoThe FDA has approved the oral combination of decitabine/cedazuridine (Inqovi) with venetoclax (Venclexta) for adults with newly diagnosed acute myeloid leukemia who are at least 75 years old or hav…onclive · 5mo agoApprovalPositive